Sangamo +15% AH as first study of ZFN genome editing published in NEJM

|About: Sangamo BioSciences, Inc. (SGMO)|By:, SA News Editor

Sangamo Biosciences (SGMO) +15.4% AH after announcing the publication in the New England Journal of Medicine of the first clinical study of its proprietary zinc finger nuclease-based genome editing technology in humans.

SGMO says data from the study, carried out in HIV-positive subjects, shows the T-cell genome can be safely engineered to mimic a naturally occurring mutation that provides resistance to HIV infection, demonstrating the feasibility of this genome editing approach to achieve functional control of HIV.